Hubertus von Baumbach, Boehringer Ingelheim chairman (Stefan Puchner/picture-alliance/dpa/AP Images)

Boehringer In­gel­heim kicks off €350M R&D cen­ter in Ger­many

In line with its ex­pec­ta­tions of snag­ging about 20 new drug ap­provals over the next sev­en years, to­day Boehringer In­gel­heim in­au­gu­rat­ed a new Ger­many-based re­search cen­ter, in­to which the com­pa­ny in­vest­ed €350 mil­lion (more than $386.5 mil­lion).

The Bi­o­log­i­cals De­vel­op­ment Cen­ter, sit­u­at­ed on Boehringer’s cam­pus in Bib­er­ach, will strength­en its bio­phar­ma­ceu­ti­cals de­vel­op­ment, which ac­counts for about 50% of the com­pa­ny’s R&D pipeline. The cen­ter is the largest sin­gle in­vest­ment in Ger­many from the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.